LPL Financial’s Endocyte, Inc. Common Stock ECYT Stock Holding History

LPL Financial’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-13,060	Closed	-$42K	–	3136
2016 Q1	$42K	Sell	13,060 -800	-6%	-$2.61K	﹤0.01%	3019
2015 Q4	$54K	Buy	+13,860	New	+$63.8K	﹤0.01%	3040
2014 Q3	–	Sell	-10,590	Closed	-$70K	–	2818
2014 Q2	$70K	Sell	10,590 -335	-3%	-$3.77K	﹤0.01%	2617
2014 Q1	$260K	Buy	+10,925	New	+$158K	﹤0.01%	2236

Other funds holding ECYT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LPL Financial's ECYT Position: Q2 2016 in Review

LPL Financial sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2016, closing a stake of 13,060 shares — an estimated $42K sold.

LPL Financial first reported a position in ECYT in Q1 2014 and held it in 4 quarters. The position peaked at $260K in Q1 2014. 96 funds tracked by Wall St. Rank hold ECYT as of Q2 2016.

LPL Financial reported no remaining Endocyte, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
LPL Financial sold 13,060 Endocyte, Inc. Common Stock shares in Q2 2016, an estimated $42K.
LPL Financial first reported a position in Endocyte, Inc. Common Stock in Q1 2014 and held it in 4 quarters.
LPL Financial's Endocyte, Inc. Common Stock position peaked at $260K in Q1 2014.
96 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2016.

Based on LPL Financial's 13F filing for Q2 2016, filed 15 Aug 2016.